《自发性早产风险蛋白质生物标志物的分析验证》[临床质谱学3（2017）25 - 38]的勘误
Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38].
作者信息
Bradford Chad, Severinsen Rob, Pugmire Trina, Rasmussen Matison, Stoddard Kathryn, Uemura Yuta, Wheelwright Spencer, Mentinova Marija, Chelsky Daniel, Hunsucker Stephen W, Kearney Paul, Hickok Durlin, Fleischer Tracey C, Ichetovkin Ilia, Boniface J Jay, Critchfield Gregory C, Peltier John M
机构信息
Sera Prognostics, Inc., 2749 East Parleys Way, Suite 200, Salt Lake City, UT 84109, USA.
Caprion Biosciences, 201 Avenue Président Kennedy, Suite 3900, Montréal, Québec H2X 3Y7, Canada.
出版信息
J Mass Spectrom Adv Clin Lab. 2022 Aug 9;25:71. doi: 10.1016/j.jmsacl.2022.07.007. eCollection 2022 Aug.
Abstract
[This corrects the article DOI: 10.1016/j.clinms.2017.06.002.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.clinms.2017.06.002。]
相似文献
1
Corrigendum to "Analytical validation of protein biomarkers for risk of spontaneous preterm birth" [Clin. Mass Spectrom. 3 (2017) 25-38].
J Mass Spectrom Adv Clin Lab. 2022 Aug 9;25:71. doi: 10.1016/j.jmsacl.2022.07.007. eCollection 2022 Aug.
2
Corrigendum to "Instability of 7-aminoclonazepam in frozen storage conditions" [Clin. Mass Spectrom. 9 (2018) 23-24].
J Mass Spectrom Adv Clin Lab. 2022 Sep 24;26:34. doi: 10.1016/j.jmsacl.2022.09.006. eCollection 2022 Nov.
3
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45].
J Mass Spectrom Adv Clin Lab. 2022 Aug 13;25:72. doi: 10.1016/j.jmsacl.2022.08.001. eCollection 2022 Aug.
4
Corrigendum to "Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease" [Clin. Mass Spectrom. 14 (Part B) (2019) 74-82].
J Mass Spectrom Adv Clin Lab. 2022 Sep 28;26:35. doi: 10.1016/j.jmsacl.2022.08.002. eCollection 2022 Nov.
5
Corrigendum to "Observation of a positive interference in LC-MS/MS measurement of d6-25-OH-vitamin D3" [Clin. Mass Spectrom. 3 (2017) 22-24].
J Mass Spectrom Adv Clin Lab. 2022 Sep 9;26:20. doi: 10.1016/j.jmsacl.2022.09.002. eCollection 2022 Nov.
6
Corrigendum to "Manipulating trypsin digestion conditions to accelerate proteolysis and simplify digestion workflows in development of protein mass spectrometric assays for the clinical laboratory" [Clin. Mass Spectrom. 6C (2018) 1-12].
Clin Mass Spectrom. 2018 Aug 30;10:33-34. doi: 10.1016/j.clinms.2018.08.005. eCollection 2018 Dec.
7
Corrigendum to "Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects" [Clin. Mass Spectrom. 9 (2018) 7-17].
J Mass Spectrom Adv Clin Lab. 2022 Oct 26;26:47. doi: 10.1016/j.jmsacl.2022.10.001. eCollection 2022 Nov.
8
Corrigendum to "Development and validation of a multiplexed LC-MS/MS ketone body assay for clinical diagnostics" [J. Mass Spectrom. Adv. Clin. Lab 31 (2024) 49-58].
J Mass Spectrom Adv Clin Lab. 2024 Jul 17;33:21. doi: 10.1016/j.jmsacl.2024.07.001. eCollection 2024 Aug.
9
Erratum regarding missing Declaration of Competing Interest Statements in previously published articles.
J Mass Spectrom Adv Clin Lab. 2021 Jan 29;20:48. doi: 10.1016/j.jmsacl.2021.01.001. eCollection 2021 Apr.
10
Corrigendum to "Is IVF/ICSI an Independent Risk Factor for Spontaneous Preterm Birth in Singletons? A Population-Based Cohort Study".
Biomed Res Int. 2019 Apr 3;2019:4940314. doi: 10.1155/2019/4940314. eCollection 2019.
引用本文的文献
1
Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial.
Diagnostics (Basel). 2024 Jul 9;14(14):1462. doi: 10.3390/diagnostics14141462.
2
Better Estimation of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating.
J Clin Med. 2022 May 19;11(10):2885. doi: 10.3390/jcm11102885.
3
Is there a maternal blood biomarker that can predict spontaneous preterm birth prior to labour onset? A systematic review.
PLoS One. 2022 Apr 4;17(4):e0265853. doi: 10.1371/journal.pone.0265853. eCollection 2022.
4
Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study.
J Clin Med. 2021 Oct 29;10(21):5088. doi: 10.3390/jcm10215088.
5
Design and Characterization of a Novel Blood Collection and Transportation Device for Proteomic Applications.
Diagnostics (Basel). 2020 Dec 2;10(12):1032. doi: 10.3390/diagnostics10121032.
6
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1973-1982. doi: 10.1158/1055-9965.EPI-20-0543. Epub 2020 Jul 30.
7
The building blocks of successful translation of proteomics to the clinic.
Curr Opin Biotechnol. 2018 Jun;51:123-129. doi: 10.1016/j.copbio.2017.12.011. Epub 2018 Feb 7.
Zotero 插件